Opdivo(nivolumab) is an immunotherapy used to treat a variety of cancer types, including melanoma. It is designed to help turn on the immune system to help fight cancer. It is not yet clear what the optimum duration of therapy with Opdivo is following a complete response to therapy, but it...
Opdivo(nivolumab) andYervoy(ipilimumab) are two anticancer medications. While they are both effective treatment options for many different types of cancer, research shows they work better when taken together for some types of cancer. What are Opdivo and Yervoy? Opdivo and Yervoy are two types of ...
In the case of ovarian cancer, historically there has been a lack of reliable screening strategies; however, the clinical value of ctDNA-based assays have since been demonstrated [82]. The first study on the application of LB for screening ovarian cancer, conducted by Cohen et al., was base...
indication," the company said in an emailed statement. BioMarin had such a program for its medicine Vimizim, for a rare disease, before it was approved earlier this year. The drug Sloan was seeking, BioMarin said, "is in the early stages of development," and doesn't yet meet that ...
Combined with Tilsotolimod/Nivolumab/Ipilimumab NCT03865082 [86] Empty Cell CMP-001 Squamous Cell Carcinoma of Head and Neck II Active, not recruiting i.t. Combined with Pembrolizumab NCT04633278 [87] Empty Cell Triple Negative Breast Cancer II Active, not recruiting i.t. As a single agent ...
nivolumab and pembrolizumab, are the first ICIs approved for the treatment of recurrent HNSCC [27]. Through the PD-1/PD-L1 pathway, these immunotherapeutic drugs suppress inhibitory signals to boost the cellular immune response induced by T cells [28]. Pembrolizumab was approved for patients whose...
All the patients for whom I was using [single-agent] nivolumab or pembrolizumab [Keytruda] are getting [nivolumab/relatlimab]. I still haven’t necessarily switched to use this drug in patients who I thought would get nivolumab/ipilimumab. And the longer we’re using it, the more patien...
You’re either going to go for a straightforward single agent PD-1 blocking agent like pembrolizumab or nivolumab, or you’re going to pay attention to the most recent data that was published in JCO and say to yourself, well, since this is a V600E mutated patient, why coul...